Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 6,734 | 4,494 |
| Amortization of right-of-use operating lease assets | 6,990 | 5,177 |
| Amortization of other assets | 1,361 | 1,180 |
| Amortization of discount on investments, net | (9,533) | (12,978) |
| Amortization of debt issuance costs | 4,150 | 3,288 |
| Non-cash royalty revenue related to sale of royalties | (22,387) | (24,894) |
| Non-cash interest related to sale of future royalties | 34,538 | 37,165 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's D&A?
- Ionis Pharmaceuticals (IONS) reported D&A of $700K in Q2 2026.
- How has Ionis Pharmaceuticals's D&A changed year-over-year?
- Ionis Pharmaceuticals's D&A increased by 17.1% year-over-year, from $598K to $700K.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Ionis Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude